Hypercalcemia

Hypercalcemia is a condition characterized by elevated levels of calcium in the blood. It can result from a variety of underlying disorders and may affect multiple organ systems. Understanding calcium physiology and the causes of hypercalcemia is essential for proper diagnosis and management.

Physiology of Calcium Homeostasis

Normal Calcium Regulation

Calcium homeostasis is tightly controlled by hormonal regulation to maintain optimal serum levels. Key regulators include:

• Parathyroid Hormone (PTH): Secreted by the parathyroid glands, PTH increases serum calcium by stimulating bone resorption, enhancing renal calcium reabsorption, and activating vitamin D.
• Vitamin D Metabolism: Active vitamin D (calcitriol) increases intestinal absorption of calcium and phosphate, contributing to serum calcium regulation.
• Calcitonin: Produced by the thyroid gland, calcitonin lowers serum calcium by inhibiting bone resorption and promoting renal excretion.

Calcium Distribution

Calcium in the body is distributed among several compartments:

• Serum Calcium: Exists in three forms: ionized (physiologically active), protein-bound (mainly to albumin), and complexed with anions.
• Bone Storage: The majority of calcium is stored in bone as hydroxyapatite, serving as a reservoir to maintain serum levels.
• Intracellular Calcium: Plays a critical role in muscle contraction, neurotransmission, and enzymatic processes.

Etiology

PTH-Mediated Hypercalcemia

Hypercalcemia may result from conditions that increase PTH secretion, leading to elevated serum calcium:

• Primary Hyperparathyroidism: Excess PTH production due to parathyroid adenoma, hyperplasia, or carcinoma.
• Familial Hypocalciuric Hypercalcemia: A genetic disorder causing mild hypercalcemia with inappropriately normal or elevated PTH levels.

Non-PTH-Mediated Hypercalcemia

Several conditions cause hypercalcemia independent of PTH activity:

• Malignancy-Associated Hypercalcemia: Tumors may produce PTH-related peptide or cause bone metastases leading to calcium release.
• Vitamin D Intoxication: Excessive intake of vitamin D or its analogs increases intestinal calcium absorption.
• Granulomatous Diseases: Conditions such as sarcoidosis or tuberculosis can activate vitamin D in macrophages, elevating calcium.
• Medications: Thiazide diuretics and lithium may contribute to hypercalcemia.

Other Causes

• Endocrine disorders including thyrotoxicosis and adrenal insufficiency.
• Prolonged immobilization, particularly in patients with high bone turnover.

Clinical Presentation

Symptoms

The clinical manifestations of hypercalcemia vary depending on the severity and rapidity of calcium elevation. Common symptoms include:

• Neurological: Fatigue, confusion, lethargy, depression, and in severe cases, stupor or coma.
• Gastrointestinal: Nausea, vomiting, constipation, abdominal pain, and anorexia.
• Renal: Polyuria, polydipsia, nephrolithiasis, and impaired renal concentrating ability.
• Cardiovascular: Hypertension, arrhythmias, and shortened QT interval on electrocardiogram.

Signs

Physical examination may reveal subtle or overt signs associated with hypercalcemia:

• Dehydration due to polyuria and reduced oral intake.
• Muscle weakness and hypotonia.
• Cardiac manifestations such as bradyarrhythmias or heart block in severe cases.

Diagnosis

Laboratory Evaluation

Diagnosis of hypercalcemia relies on laboratory confirmation and identification of the underlying cause:

• Serum total calcium and ionized calcium measurements to confirm elevation.
• Parathyroid hormone (PTH) levels to differentiate PTH-mediated versus non-PTH-mediated hypercalcemia.
• Vitamin D metabolites (25-hydroxy and 1,25-dihydroxyvitamin D) to assess for vitamin D intoxication or granulomatous disease.
• Renal function tests including serum creatinine and blood urea nitrogen.

Imaging Studies

Imaging can help identify structural causes or complications of hypercalcemia:

• Neck ultrasound or sestamibi scan for detecting parathyroid adenomas.
• Bone scan or radiographs to evaluate for lytic lesions or metastatic disease.

Management

Acute Management

Acute or severe hypercalcemia requires prompt intervention to lower serum calcium levels and prevent complications:

• Hydration: Intravenous normal saline to correct volume depletion and enhance renal calcium excretion.
• Loop Diuretics: Administered after adequate hydration to promote calcium excretion in urine.
• Calcitonin: Rapid-acting hormone therapy to temporarily reduce serum calcium by inhibiting bone resorption.
• Bisphosphonates: Used in malignancy-related hypercalcemia to inhibit osteoclast-mediated bone resorption.

Long-Term Management

Long-term treatment targets the underlying cause and prevents recurrence:

• Surgical intervention for primary hyperparathyroidism, such as parathyroidectomy.
• Treatment of malignancy with chemotherapy, radiation, or targeted therapy.
• Regular monitoring of serum calcium levels and renal function.
• Lifestyle modifications and review of medications that may contribute to hypercalcemia.

Complications

Persistent or severe hypercalcemia can lead to multiple organ system complications:

• Renal: Nephrolithiasis, nephrocalcinosis, and chronic kidney disease.
• Cardiovascular: Arrhythmias, shortened QT interval, and potential heart block.
• Neurocognitive: Confusion, lethargy, depression, and in severe cases, coma.
• Skeletal: Osteoporosis, bone pain, and increased fracture risk.

Prognosis

The prognosis of hypercalcemia depends on the underlying cause, severity, and timeliness of treatment. Mild hypercalcemia due to primary hyperparathyroidism or medication-induced causes generally has a favorable outcome with appropriate management. Severe or prolonged hypercalcemia, particularly related to malignancy, carries a higher risk of morbidity and mortality. Early detection and treatment of the underlying disorder are critical for improving long-term outcomes.

References

1. Shoback D, Gardner DG, et al. Greenspan’s Basic & Clinical Endocrinology. 10th ed. New York: McGraw-Hill; 2020.
2. Jameson JL, De Groot LJ, editors. Endocrinology: Adult and Pediatric. 7th ed. Philadelphia: Elsevier; 2016.
3. Lehmann G, Lee H, et al. Hypercalcemia: Diagnosis and Management. N Engl J Med. 2018;378(19):1792-1803.
4. Walker MD, Silverberg SJ. Hypercalcemia in primary hyperparathyroidism. J Clin Endocrinol Metab. 2018;103(12):4283-4295.
5. Bilezikian JP, Brandi ML, et al. Management of hypercalcemia. Lancet Diabetes Endocrinol. 2018;6(6):476-488.
6. Thakker RV, Clarke BL, et al. Primary hyperparathyroidism. Nat Rev Dis Primers. 2018;4:36.
7. Rosenthal MH, Brown EM. Clinical review: Disorders of calcium metabolism. J Clin Endocrinol Metab. 2019;104(9):3993-4005.
8. Rossi ML, Tamma R, et al. Hypercalcemia: Clinical features and therapeutic approaches. Clin Cases Miner Bone Metab. 2017;14(3):221-228.